Marinus Pharma (NASDAQ: MRNS) reported Q2 EPS of ($0.65), $0.04 better than the analyst estimate of ($0.69). Revenue for the quarter came in at $1.91 million versus the consensus estimate of $2.7 million.

For earnings history and earnings-related data on Marinus Pharma (MRNS) click here.